Clinical Trial

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens, for the adjuvant treatment of patients with biliary malignant tumors after radical resection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-20.
Trial Details
NCT Number NCT07368803
Lead Sponsor Yifan Wang
Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions Biliary Malignant Tumors
Enrollment 20 participants
Start Date 2025-09-11
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-03